RNAi modulation of MLL-AF4 and uses thereof

Details RNAi modulation of MLL-AF4 and uses thereof RNAi modulation of MLL-AF4 and uses thereof

2010-02-04

2011-10-11

Whiteman, Brian (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

08034793

ABSTRACT:
The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.

REFERENCES:
patent: 7045292 (2006-05-01), Mai
patent: 7361752 (2008-04-01), Heidenreich et al.
patent: 7674779 (2010-03-01), Heidenreich et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2007/0004664 (2007-01-01), McSwiggen et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
AF024541 (Oct. 24, 1997, [online] Bethesda, MD USA: United States National Library of Medicine [retrieved on Dec. 20, 2010]. Retrieved from: GenBank, Accession No. AF024541).
Agrawal, S., et al., “Antisense oligonucleotides: towards clinical trials.” Trends in Biotechnology. Oct. 1996, vol. 14, pp. 376-387.
Bass, B., “The short answer,” Nature, May 24, 2001, pp. 428-429, vol. 411.
Elbashir, S., et al., “Analysis of gene function in somatic mammalian cells using small interfering RNAs,” Methods, 2002, pp. 199-213, vol. 26.
Elbashir, S., et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture,” Nature, May 24, 2001, p. 494-498, vol. 411.
Elbashir, S., et al., “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate”, The EMBO Journal, 2001, pp. 6877-6888, vol. 20, No. 23.
Elbashir, S., et al., “RNA Interference is Mediated by 21-and 22 Nucleotide RNAs,” Genes & Development, 2001, pp. 188-200, vol. 15.
Fire, A., “RNA-triggered Gene Silencing,” Trends in Genetics, Sep. 1999, pp. 358-363, vol. 15, No. 9.
Fire, A., et al., “Potent and Specific Genetic Interference by Double Stranded RNA inCaenorhabditis elegans,” Nature, Feb. 19, 1998, pp. 806-811, vol. 391.
Tuschl, T., “Functional genomics: RNA sets the standard,” Nature, Jan. 16, 2003, vol. 421, No. 6920, pp. 220-221.
Tuschl T., “RNA Interference and Small Interfering RNAs” Chembiochem, 2001, pp. 239-245, vol. 2.
Tuschl, T., et al., “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,” Molecular Interventions, 2002, pp. 158-167, vol. 2, No. 3.
Tuschl, T., “Mammalian RNA Interference,” RNAi, A Guide to Gene Silencing, Chapter 13, G.J. Hannon (ed,), 2003, pp. 265-295.
Tuschl, T., et al., “Targeted mRNA Degradation by Double-Stranded RNA In Vitro,” Genes & Development, 1999, pp. 3191-3197, vol. 13.
Tuschl, T., “Expanding small RNA interference,” Nature Biotechnology, May 2002, pp. 446-448, vol. 20.
Vickers, T., et al., “Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents,” The Journal of Biological Chemistry, Feb. 28, 2003, pp. 7108-7118, vol. 278, No. 9.
Domer et al., “Acute mixed-lineage leukemia t(4;11)(q21;a23) generates an MLL-AF4 fusion product” Proc. Natl. Acad. Sci. USA 90:7884-7888 (1993).
Gu et al., “The t(4;11) Chromosome Translocation of Human Acute Leukemias Fuses the ALL-1 Gene, Related toDrosophila trithorax, to the AF-4 Gene” Cell 71:701-708 (1992).
Marschalek et al., “Molecular analysis of the chromosomal breakpoint and fusion transcripts in the acute lymphoblastic SEM cell line with chromosomal translocation t(4;11)” Br. J. Haematol. 90:308-320 (1995).
GenBank Accession No. L22179, “Human MLL-AF4 der(11) fusion protein mRNA, complete cds” Sep. 15, 1993.
Sledz et al., “Activation of the interferon system by short-interfering RNAs” Nat. Cell Biol. 5:834-839 (2003).
Uckun et al., “Leukemic Cell Growth in SCID Mice as a Predictor of Relapse in High-Risk B-Lineage Acute Lymphoblastic Leukemia” Blood 85:873-878 (1995).
Pocock et al., “BCL-2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia associated with the t(4;11)(q21;q23) translocation” Br. J. Haematol. 90:855-867 (1995).
Office Action for Canada Patent Application No. 2,590,768, Feb. 25, 2011, 5 pages.
Examiner's first report on Australia Patent Application No. 2005316384, Oct. 18, 2010, 2 pages.
Examination Report for European Patent Application No. EP 05854523.7, Oct. 4, 2010, 5 pages.

Affiliated with

Also associated with

Rating

RNAi modulation of MLL-AF4 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with RNAi modulation of MLL-AF4 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi modulation of MLL-AF4 and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4255197